Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAYLOR-002: Neoadjuvant Culmerciclib + AI in HR+/HER2- Early Breast Cancer
NCT07616453Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- May 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of culmerciclib in breast cancer, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Complete cell cycle arrest at 4 weeks. Started May 2026; status: recruiting.
02
Drugs
culmerciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07616453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07616453.